Drug Approval | June 05, 2025
UK MHRA approves aumolertinib to treat non-small cell lung cancer
Aumolertinib can be used in patients who have tested positive for a mutation in a gene called epidermal growth factor receptor
Aumolertinib can be used in patients who have tested positive for a mutation in a gene called epidermal growth factor receptor
Rifaximin tablets had annual sales of US$ 2672.9 mn in the United States (IQVIA MAT March 2025)
Approximately 35% of male cancer patients and 12% of female cancer patients at Paras Health were diagnosed with tobacco-related cancers
The company also announced results for the third quarter, reporting sales at Rs. 992 crore, flat versus year ago
Akums invested Rs. 272 crore in capital expenditure during FY25
For the full year FY25, net profit soared 12x to Rs 345 crore
Isotretinoin capsules are indicated to treat severe, disfiguring nodular acne
Five-year follow-up data from the Phase 3 ARCHES trial shows XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces risk of death by 30%
Merck KGaA, Darmstadt, Germany announced the presentation of new oncology data across more than 12 tumor types at ASCO 2025
IICP is a registered charitable society working in the disability sector since 1974
Subscribe To Our Newsletter & Stay Updated
